IDEXX LABORATORIES INC /DE — Director's Dealing 2015

Aug 12, 2015

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: IDEXX LABORATORIES INC /DE (IDXX)
CIK: 0000874716
Period of Report: 2015-08-10

Reporting Person: Williams Michael J PhD (Executive Vice President)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2015-08-10	Common Stock	S	3194	$77.96	Disposed	30086	Direct
2015-08-10	Common Stock	M	5000	$26.66	Acquired	35086	Direct
2015-08-10	Common Stock	M	2482	$17.19	Acquired	37568	Direct
2015-08-10	Common Stock	S	6532	$77.93	Disposed	31036	Direct
2015-08-10	Common Stock	S	950	$77.29	Disposed	30086	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2015-08-10	Non-Qualified Stock Option (Right to buy)	$17.19	M	2482	Disposed	2016-02-13	Common Stock (2482)	Direct
2015-08-10	Non-Qualified Stock Option (Right to buy)	$26.66	M	5000	Disposed	2017-02-13	Common Stock (5000)	Direct

Footnotes

F1: The number of securities reported reflects a 2-for-1 stock split in the form of a 100% stock dividend on IDEXX Laboratories, Inc. common stock paid on June 15, 2015 (the "Stock Split") and includes 82 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on 6/30/2015.

F2: The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $77.75 and $78.03, inclusive. The reporting person hereby undertakes to provide upon request to SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range.

F3: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that became exercisable as to 4,149 shares on 2/14/2010 and 2/14/2013, 4,150 shares on 2/14/2011 and 2/14/2012 and the remaining 1,241 shares on 2/14/2014, without giving effect to the Stock Split. The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.

F4: Grant of option to buy shares of IDEXX Laboratories Inc. common stock that became exercisable as to 3,834 shares on 2/14/2011, 2/14/2012, 2/14/2013 and 2/14/2014 and the remaining 1,959 shares on 2/14/2015, without giving effect to the Stock Split. The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.